On the evening of August 24th, Simore International (06969.HK) published its financial report for the first half of 2022 on the Hong Kong Stock Exchange platform. Below are the key points of information compiled by 2FIRSTS.
In the first half of 2022, revenue was RMB 5.65 billion, a 18.7% decrease from the same period last year when it was RMB 6.955 billion. Adjusted net profit for this year was RMB 1.436 billion compared to RMB 2.975 billion last year, a 51.7% decrease. As of June 30, 2022, total assets were RMB 23.66 billion, a 3.4% increase from the same period last year. Debt ratio was 16.8% as of June 30, 2022, a 1% increase from last year. Research and development expenses increased by 156% compared to the same period last year, reaching RMB 604 million. Sales to corporate customers comprised 90.1%, while sales to retail customers were at 9.9%. In the same period last year, sales to corporate customers were at 93.4% and sales to retail customers were at 6.6%. Among sales to corporate customers, the US accounted for 28.6%, mainland China accounted for 30%, and other countries and regions accounted for 31.5%. Compared to the same period last year, the proportion of sales to the US decreased while the proportion of sales to other countries and regions increased. The company launched a ceramic atomization core technology platform, Feelm Max, for disposable electronic atomization devices and introduced its disposable electronic atomization products to overseas markets which received widespread approval and achieved significant sales growth, as indicated in its financial report. One atomization drug delivery device has been approved by China's relevant regulatory agency to enter the special approval process for innovative medical devices, with hopes of achieving commercialization soon. Three wholly-owned subsidiaries of Smoore International, Shenzhen Mackwell Technology Co., Ltd., Shenzhen Mako Brothers Technology Co., Ltd., and Shenzhen Vapcell Technology Co., Ltd., have been awarded tobacco monopoly enterprise production licenses.
Click here to download the original PDF of Simo's financial report.
To read more on Symrise's half-yearly financial report, please click on the following title link to be directed:
Simul announced that it will only accept orders commissioned through the national standard technology review committee. Chen Zhiping stated that Simul will only focus on three specific business areas going forward.
Statement:
1. This article is intended for internal industry research and exchange only. It does not offer any investment or brand recommendations and should not be taken as a basis for any investment decisions. 2. The data and analysis conclusions cited in this article have not been confirmed with the companies in writing. All data should be considered based on the company’s official releases.
This article is original content from 2FIRSTS Technology Co. Ltd. in Shenzhen. The copyright and licensing rights belong to the company, and no individual or organization may use, copy, or otherwise infringe upon the company's copyright for commercial reprinting without authorization. Any violation will result in the company reserving the right to pursue legal action.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
